Pfizer Settles Viagra Patent Litigation With Teva

Pfizer PFE announced that it has settled its litigation against Teva Pharmaceuticals, USA Inc., relating to Pfizer's patent covering the use of Viagra® to treat erectile dysfunction (sildenafil… Pfizer Inc. announced that it has settled its litigation against Teva Pharmaceuticals, USA TEVA, relating to Pfizer's patent covering the use of Viagra® to treat erectile dysfunction (sildenafil citrate 25, 50, and 100 mg tablets), which expires in April 2020 (including pediatric exclusivity). As a result of the settlement, Teva will be allowed to launch a generic version of Viagra® in the United States on December 11, 2017, or earlier under certain circumstances. Teva will pay Pfizer a royalty for a license to produce its generic version. The terms of the settlement agreement are otherwise confidential. Teva has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of Viagra®. See full press release